Next Article in Journal
Mechanisms of Rebaudioside A Degradation and Ingredient-Sweetener Interactions in Beverages during Storage
Next Article in Special Issue
Synthesis and Activity of Triazole-Adenosine Analogs as Protein Arginine Methyltransferase 5 Inhibitors
Previous Article in Journal
Vincamine Modulates the Effect of Pantoprazole in Renal Ischemia/Reperfusion Injury by Attenuating MAPK and Apoptosis Signaling Pathways
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 4
10.3390/molecules27041381
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Improved Cell-Potent and Selective Peptidomimetic Inhibitors of Protein N-Terminal Methyltransferase 1

by
Guangping Dong
1,
Iredia D. Iyamu
1,
Jonah Z. Vilseck
2,
Dongxing Chen
1 and
Rong Huang
1,*
1
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Institute for Drug Discovery, Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA
2
Department of Biochemistry and Molecular Biology, Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
*
Author to whom correspondence should be addressed.
Molecules 2022, 27(4), 1381; https://doi.org/10.3390/molecules27041381
Submission received: 21 December 2021 / Revised: 29 January 2022 / Accepted: 1 February 2022 / Published: 18 February 2022
(This article belongs to the Special Issue Design and Synthesis of Chemical Probes for Epigenetic Modification Enzymes and Proteins)
Browse Figures
Versions Notes

Abstract

:
Protein N-terminal methyltransferase 1 (NTMT1) recognizes a unique N-terminal X-P-K/R motif (X represents any amino acid other than D/E) and transfers 1–3 methyl groups to the N-terminal region of its substrates. Guided by the co-crystal structures of NTMT1 in complex with the previously reported peptidomimetic inhibitor DC113, we designed and synthesized a series of new peptidomimetic inhibitors. Through a focused optimization of DC113, we discovered a new cell-potent peptidomimetic inhibitor GD562 (IC50 = 0.93 ± 0.04 µM). GD562 exhibited improved inhibition of the cellular N-terminal methylation levels of both the regulator of chromosome condensation 1 and the oncoprotein SET with an IC50 value of ~50 µM in human colorectal cancer HCT116 cells. Notably, the inhibitory activity of GD562 for the SET protein increased over 6-fold compared with the previously reported cell-potent inhibitor DC541. Furthermore, GD562 also exhibited over 100-fold selectivity for NTMT1 against several other methyltransferases. Thus, this study provides a valuable probe to investigate the biological functions of NTMT1.

1. Introduction

Protein α-N-terminal methyltransferases (NTMTs/NRMTs) catalyze the addition of 1–3 methyl group(s) to the protein α-N-termini from the cofactor S-adenosyl-L-methionine (SAM). Protein N-terminal methyltransferase 1/2 (NTMT1/2, METTL11A/B) are the two reported members of this family that recognize a unique N-terminal X-P-K/R motif (X represents any amino acid other than D/E) [1,2]. To date, the regulator of chromosome condensation 1 (RCC1), the tumor suppressor retinoblastoma 1 (RB1), oncoprotein SET, centromere protein A/B (CENP-A/B), damaged DNA-binding protein 2 (DDB2), poly(ADP-ribose) polymerase 3 (PARP3), Obg-like ATPase 1 (OLA1), and MORF-related gene on chromosome 15 (MRG15) have been reported as physiological substrates for NTMT1 [1,3,4,5,6,7,8]. Though protein α-N-terminal methylation is evolutionarily conserved across different species [8], the knowledge of its functions remains scant. Unlike aliphatic side-chain amines (pKa: 10.5), full methylation of the protein α-N-terminal amine (pKa: 6~8) would alter both the hydrophobicity and charge state [9]. The resulting positive charge at protein α-N-terminus strengthens the interactions of proteins to their respective binding partners, as exemplified in RCC1 and CENP-A [1,3,10]. Besides, the α-N-terminal methylation of DDB2 facilitates its nuclear localization to cyclobutane pyrimidine dimer (CPD) foci [4]. In addition, NTMT1 has been implicated in regulating mitosis, DNA damage repair, stem cell maintenance, and cervical cancer cell proliferation and migration [1,11,12,13]. Thus, cell-potent inhibitors would serve as valuable tools to study the functions and roles of NTMT1/2.
Guided by the unique substrate-binding mode of NTMT1/2, we have reported several peptidomimetic inhibitors with modest cellular potency [14,15]. The first peptidomimetic inhibitor BM30 displayed an IC50 value of 0.89 ± 0.1 µM and over 100-fold selectivity for NTMT1/2 among a panel of 41 methyltransferases [14]. To improve the cellular uptake of peptidomimetic inhibitors [14], substituting the phenol group of BM30 with a naphthalene ring yielded DC113, with improved inhibition activity (IC50 = 0.1 ± 0.01 µM) and cell permeability (Figure 1) [15]. However, DC113 only decreased ~50% of the cellular me3-RCC1 level at 1 mM in HCT116 cells [15]. The co-crystal structure of NTMT1-DC113 (Figure 1) confirmed a similar binding mode of DC113 as the peptide substrate SPKRIA [15]. As the Pro2 and Lys3 moieties in the peptide substrates and peptidomimetic inhibitors are essential to the binding [14], the subsequent replacement of Arg4 of DC113 with benzamide provided DC541, enhancing cellular inhibition (IC50 of ~100 μM) on the me3-RCC1 level in HCT116 compared to DC113 [15]. Thus, we hypothesized that further introducing hydrophobic groups would promote cellular potency without perturbing the binding to NTMT1. Herein, we proposed a focused optimization on the C-region of DC113 or DC541 to enhance cellular potency (Figure 1).

2. Design

Compared to DC113, DC541 exhibited about 10-fold enhanced cellular inhibition with a ~3-fold decrease in its inhibitory activity on recombinant NTMT1 [15], suggesting that optimization of the C-region of the ligand scaffold is a feasible strategy to improve the hydrophobicity and enhance the cell potency of the compounds (Figure 1). As the C-region is exposed to solvent, we expect minimal interferences with the binding to NTMT1. In addition, incorporating non-amino acid functional groups has the potential to improve the compound’s proteolytic stability [15]. Therefore, we hypothesized that incorporating more hydrophobic groups at the C-region of DC541 would increase ligand hydrophobicity, permeability, and proteolytic stability without significantly affecting the binding to NTMT1. Thus, we introduced different R groups to increase the hydrophobicity considering its positive correlation to permeability [16], using cLogP as the parameter to track hydrophobicity in the design [17].

3. Synthesis

All the peptidomimetic inhibitors were synthesized in the solution phase, as shown in Scheme 1 [15]. Compound 2 was synthesized through the standard amide coupling of HCl•Lys(Boc)-COMe with Naphthalene-Pro. Subsequent hydrolysis of 2 provided 3. The final peptidomimetic inhibitors 1a–k were prepared by the reactions of various amines with 3, followed by the acidic treatment with 4 N HCl in 1,4-Dioxane.
Reagent and conditions: (a) HCl•Lys(Boc)-COMe, HBTU, HOBt, DIPEA, DMF, r.t.; (b) LiOH•H2O, MeOH/H2O, 0 °C to r.t.; (c) R-NH2, HBTU, HOBt, DIPEA, DMF, r.t.; (d) 4N HCl in dioxane, 0 °C to r.t.

4. Structure–Activity Relationship

Inhibitory activities of all synthesized compounds were determined with an established SAHH-coupled fluorescence assay [14,15]. To increase hydrophobicity, we first replaced the benzamide ring with a bromophenyl group to produce 1a and 1b with higher cLogP values than DC541 (Table 1). Both compounds showed ~2-fold increased inhibition compared to DC541, suggesting the bromide may form a halogen bond with NTMT1. Next, we varied the carbon length between the phenyl ring and the amide group to produce 1c–e, displaying inhibitory activities with IC50 values ranging from 0.65 to 0.93 µM. The comparable inhibition of 1c–e suggested a marginal effect of chain linker length on the inhibitory activity. To explore the importance of aromaticity at the C-region, we replaced the phenyl ring of 1c with a cyclohexyl ring to produce 1g, exhibiting a similar inhibition activity as 1c. As the introduction of the bromide at the phenyl ring led to ~2-fold enhanced inhibition for 1a,1b compared to DC541, we also added bromide to the phenyl ring of 1c at the meta- and para- positions to generate 1g and 1h, respectively. However, 1g and 1h showed marginally improved potency (less than 2-fold) compared with 1c. As N-methylation has been proven to improve the cell permeability of peptides [18], we introduced a methyl group to the C-terminal amide of 1d to produce 1i, which resulted in a 2-fold decreased inhibition. To explore the possible interaction with Tyr215 [15,19], we synthesized a biphenyl group at the C-terminal region to yield 1j (IC50 = 2.5 ± 0.09 µM), resulting in a ~3-fold inhibition reduction compared to 1d. Then, we switched the substitution position of the phenyl ring from the para to the meta position to produce 1k (IC50 = 0.69 ± 0.08 µM), rescuing the inhibition with the comparable activity as the parent compound 1d.

5. Computational Studies

To understand the contribution of different functional groups to the inhibition activities of the peptidomimetic inhibitors, we first performed a docking study using Glide software (Schrödinger) [19,20]. The IC50 values correlated well with the docking scores yielding an R2 of ~0.7 (Figure 2A). All peptidomimetic inhibitors except 1j (GD590) docked with a similar binding mode as DC541 and DC113. For example, the ε-NH2 group of the Lys3 side chain in 1a (GD556) formed electrostatic interactions with Asp177 and Asp180, while the backbone carbonyl group interacted with Tyr215 through a hydrogen bond (Figure 2B). In contrast, 1j only interacted with Asp180 and lost the hydrogen bonding with Tyr215, providing a structural explanation for its eight-fold decrease in inhibition activity compared to DC541 (Figure 2C). In support of our hypothesis, the C-terminal biphenyl ring at the meta-position in compound 1k (GD591) facilitated interactions with Asp 180, Asp 177, and Tyr215, with an additional π-π interaction between the fourth position phenyl ring and Tyr215 (Figure 2D).
Alchemical free energy calculations, which employ a flexible receptor and explicit solvation, were performed next with multisite λ-dynamics (MSλD) for a subset of compounds (1a–h) [21,22]. A good correlation between computed and experimental binding free energies (ΔGbind) was again observed with a Pearson R of 0.71 (Figure 3, Table S1). Experimental ΔGbind were estimated from the IC50 values in Table 1 [23]. Compounds 1a,1b were modeled both with and without σ-hole lone pair particles to investigate the importance of halogen bonding for these compounds. However, no significant difference was observed in computed ΔGbind, suggesting halogen bonding does not play a dominant role in binding. In contrast, all C-region phenyl rings interacted strongly with Tyr215 and formed T-shaped and offset-parallel π-π stacking conformations. Thus, the benefit of the bromine atoms in 1a,1b likely stems from its electron-withdrawing and increased dispersive character, which are known to strengthen π-π stacking interactions [24]. In molecules 1c–e, as the carbon linker was elongated, ideal π-π stacking interactions and geometries were disrupted, slightly weakening ligand complexation. For example, the optimal center of mass (COM) distances between stacked benzene rings are often ~5 Å apart [25]. Figure S1 shows a positive trend between experimental ΔGbind and increasing COM distances between substituent rings and Tyr215, measured from the MSλD trajectories. Surprisingly, as the carbon linker was extended, the consistent orientation of the methylene hydrogens pointed towards the π surface of Tyr215 (Figure 3). Though weaker than conventional hydrogen bonds, CH—π bonds have been shown to present weak attractive forces [26]. The equivalency in ΔGbind between 1c, 1d, and 1f suggests that these CH–π interactions may help sufficiently counteract the loss of π-stacking with Tyr215 through favorable dispersive interactions and hydrophobic packing.

6. Cytotoxicity

We evaluated the cytotoxicity of those peptidomimetic inhibitors (IC50 < 2 μM) in HCT116 cells through alamaBlue assay, as HCT116 cells are known for their high expression of NTMT1 [15]. Compared with DC541, all bromide compounds (1a, 1b, 1g, and 1h) and 1k displayed cytotoxicity, with GI50 values ranging from 48 μM to 135 μM (Table 2, Figure 4A). Among them, 1a, 1b, and 1k exhibited GI50 values of <70 μM, while 1g and 1h showed moderate growth inhibition against HCT116 with GI50 values of ~130 μM. All other compounds showed negligible inhibition of cell growth even at 300 μM. As NTMT1 knockout did not exhibit any significant inhibition on HCT116 cell growth [27], we reasoned that the inhibition of NTMT1 would not affect the HCT116 cell growth. Thus, we hypothesized that the growth inhibition effects of these five peptidomimetic inhibitors may be caused by off-target effects. To test our hypothesis, we selected 1a to evaluate its impact on both wild-type and NTMT1 knockout HCT116 cells (Figure 4B) [27]. Compound 1a exhibited a comparable GI50 value on HCT116 cell growth, regardless of the presence of NTMT1, suggesting the growth inhibition effect resulted from off-target effects.

7. Inhibition on Cellular N-Terminal Methylation

Next, we investigated the effects of all peptidomimetic inhibitors with GI50 > 100 µM and IC50 < 1 µM on the cellular α-N-terminal methylation level in HCT116 cells (Table 2) [15]. Then, we examined the top three cell-potent peptidomimetic inhibitors 1d–f on the dose-response of inhibition of cellular N-terminal methylation levels. Compared to compound DC541 [15], 1d–f displayed comparable or improved cellular inhibition activities on both me3-RCC1 and me3-SET (Figure 5A–C). Among them, 1d (GD562) exhibited improved cellular inhibition on me3-RCC1 with an IC50 of ~50 µM (Figure 5A). Furthermore, GD562 also inhibited me3-SET with a similar cellular IC50 value of ~50 µM, while DC541 did not show any inhibition of me3-SET level even at 300 µM in HCT116 cells [15]. As the biochemical IC50 value of GD562 was about three-fold higher than DC541, we proposed that the improved cellular inhibition of GD562 may be attributed to its increased permeability with higher cLogP than DC541.

8. Permeability

To understand the discrepancy between biochemical IC50 and cellular IC50 values, we evaluated the ability of these inhibitors to cross the cell membrane in the Parallel Artificial Membrane Permeability Assay (PAMPA) [28,29,30]. The permeability of the control compound verapamil was determined as 8.6 ± 0.98 × 10−6 cm/s, comparable to the literature value (8.8 ± 0.53 × 10−6 cm/s) [30]. As shown in Table 2, the majority of synthesized peptidomimetics showed 10- to 50-fold lower permeability compared to verapamil. The phenyl analogs 1c–e with variable carbon length showed the lowest permeability values ranging from 0.17 × 10−6 cm/s to 0.26 × 10−6 cm/s, which was about two-fold less than the cyclohexyl analog 1f with a permeability value of 0.47 × 10−6 cm/s. This suggests that acyclic rings have better cell permeability than aromatic rings. Methylation of the C-terminal amide of 1d to 1i resulted in a higher cLogP, which was also evident in a roughly two-fold improvement in cell permeability. As expected, the biphenyl analogs 1j and 1k had the higher cell permeability values of 0.9 × 10−6 cm/s and 1.3 × 10−6 cm/s due to the improved lipophilicity of the additional phenyl group. This trend of the permeability values from the PAMPA assay is proportional to that of the cLogP values, with 1j and 1k displaying the highest cLogP values of 3.8.

9. Selectivity

Since GD562 exhibited the highest cellular inhibition activity and lower cytotoxicity among all tested peptidomimetic inhibitors (Table 2), the compound was chosen for in-house selectivity studies (Figure 6) by examining its inhibition activity against a panel of five other SAM-dependent protein methyltransferases and the coupling enzyme SAHH in a fluorescence assay. The results showed that GD562 did not inhibit over 50% of those enzyme activities at 100 μM, indicating that the compound was more than 100-fold selective for NTMT1 against other methyltransferases and SAHH. Furthermore, compared with DC541 [15], GD562 showed increased selectivity for NTMT1 over PRMT1.

10. Discussion

In summary, a series of new peptidomimetic inhibitors were designed, synthesized, and evaluated based on the structures of previously reported inhibitors. We successfully optimized the cellular inhibition activity of the peptidomimetic inhibitor by introducing more hydrophobic function groups to replace the benzamide of DC541. The most cell-potent inhibitor GD562 exhibited over 100-fold selectivity over the other five SAM-dependent protein methyltransferases. Although GD562 showed decreased biochemical inhibition compared to DC541, it demonstrated an over 2-fold increase in cellular inhibition activity on me3-RCC1. In addition, it also inhibited the me3-SET with a similar IC50 as me3-RCC1. Besides, GD562 exhibited improved selectivity over DC541 regarding PRMT1. Noticeably, the cellular inhibition activity of NTMT1 by GD562 is not optimal since there is still a ~50-fold difference between its enzymatic and cellular IC50 values. Based on the PAMPA result, permeability alone did not explain the discrepancy between the biochemical and cellular IC50 values. Future directions include further improving the cellular potency of these compounds by adding substituent groups to the C-terminal phenyl ring, or testing new heterocycles at the C-region. Meanwhile, fluorescent labeling GD562 to monitor its cellular distribution would also be informative, as NTMT1 is predominantly located in the nucleus [1]. Nevertheless, GD562 is the first tetra-peptidomimetic inhibitor that can inhibit me3-RCC1 and me3-SET with an IC50 value of ~50 µM. Therefore, it can serve as a valuable tool to investigate the biological functions of NTMT1 in cells and as a new lead compound for further optimization.

Supplementary Materials

The following supporting information can be downloaded online. Table S1: MSλD Computed vs. Experimental Binding Free Energies (kcal/mol), Figure S1: Correlation between experimental binding affinities and average computed center of mass (COM) distances between C-region substituent rings and the phenyl ring of Tyr215. MS, NMR spectra, HRMS, and HPLC analysis of compounds 1a–k.

Author Contributions

R.H. devised the project and conceived the original ideas; G.D. designed, synthesized, purified, characterized, and evaluated the compounds; G.D. also performed the docking studies through Glide; I.D.I. performed the permeability study; J.Z.V. performed the computational studies through alchemical free energy calculations; D.C. prepared and characterized lead compound DC541; G.D. took the lead in writing the manuscript, while I.D.I. and J.Z.V. contributed to writing; R.H. edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

The authors acknowledge the support from NIH grants R01GM117275 (RH) and P30 CA023168 (Purdue University Center for Cancer Research).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors acknowledge the support from the Department of Medicinal Chemistry and Molecular Pharmacology (RH) at Purdue University, West Lafayette, IN, USA. J.Z.V. gratefully acknowledges the Indiana University Precision Health Initiative and Pervasive Technology Institute for supporting supercomputing and storage resources that have contributed to research results reported within this manuscript. The authors also appreciate Christine Schaner Tooley for her generous gift of the pan me3-SPK antibody and HCT116 NTMT1 knockout cell line.

Conflicts of Interest

The authors declare no competing financial interest.

Abbreviations

NTMT, protein N-terminal methyltransferase; SAM, S-5′-adenosyl-L-methionine; SAH, S-5′-adenosyl-L-homocysteines; SAHH, SAH hydrolase; MT, methyltransferase; PKMT, protein lysine methyltransferase; PRMT, protein arginine methyltransferase; PRMT1, protein arginine methyltransferase 1; TbPRMT7, Trypanosoma brucei protein arginine methyltransferase 7; G9a, euchromatic histone-lysine N-methyltransferase 2; SETD7, SET domain-containing protein 7; NNMT, nicotinamide N-methyltransferase; rt, room temperature; TFA, trifluoroacetic acid.

References

  1. Schaner Tooley, C.E.; Petkowski, J.J.; Muratore-Schroeder, T.L.; Balsbaugh, J.L.; Shabanowitz, J.; Sabat, M.; Minor, W.; Hunt, D.F.; Macara, I.G. NRMT is an α-N-methyltransferase that methylates RCC1 and retinoblastoma protein. Nature 2010, 466, 1125–1128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Petkowski, J.J.; Bonsignore, L.A.; Tooley, J.G.; Wilkey, D.W.; Merchant, M.L.; Macara, I.G.; Schaner Tooley, C.E. NRMT2 is an N-terminal monomethylase that primes for its homologue NRMT1. Biochem. J. 2013, 456, 453–462. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Sathyan, K.M.; Fachinetti, D.; Foltz, D.R. α-amino trimethylation of CENP-A by NRMT is required for full recruitment of the centromere. Nat. Commun. 2017, 8, 14678. [Google Scholar] [CrossRef] [PubMed]
  4. Cai, Q.; Fu, L.; Wang, Z.; Gan, N.; Dai, X.; Wang, Y. α-N-Methylation of Damaged DNA-Binding Protein 2 (DDB2) and Its Function in Nucleotide Excision Repair. J. Biol. Chem. 2014, 289, 16046–16056. [Google Scholar] [CrossRef] [Green Version]
  5. Dai, X.; Rulten, S.L.; You, C.; Caldecott, K.W.; Wang, Y. Identification and Functional Characterizations of N-Terminal α-N-Methylation and Phosphorylation of Serine 461 in Human Poly(ADP-ribose) Polymerase 3. J. Proteome Res. 2015, 14, 2575–2582. [Google Scholar] [CrossRef] [Green Version]
  6. Jia, K.; Huang, G.; Wu, W.; Shrestha, R.; Wu, B.; Xiong, Y.; Li, P. In vivo methylation of OLA1 revealed by activity-based target profiling of NTMT1. Chem. Sci. 2019, 10, 8094–8099. [Google Scholar] [CrossRef] [Green Version]
  7. Bade, D.; Cai, Q.; Li, L.; Yu, K.; Dai, X.; Miao, W.; Wang, Y. Modulation of N-terminal methyltransferase 1 by an N(6)-methyladenosine-based epitranscriptomic mechanism. Biochem. Biophys. Res. Commun. 2021, 546, 54–58. [Google Scholar] [CrossRef]
  8. Huang, R. Chemical Biology of Protein N-Terminal Methyltransferases. Chembiochem 2019, 20, 976–984. [Google Scholar] [CrossRef]
  9. Grimsley, G.R.; Scholtz, J.M.; Pace, C.N. A summary of the measured pK values of the ionizable groups in folded proteins. Protein Sci. 2009, 18, 247–251. [Google Scholar]
  10. Chen, T.; Muratore, T.L.; Schaner-Tooley, C.E.; Shabanowitz, J.; Hunt, D.F.; Macara, I.G. N-terminal α-methylation of RCC1 is necessary for stable chromatin association and normal mitosis. Nat. Cell Biol. 2007, 9, 596. [Google Scholar] [CrossRef]
  11. Bonsignore, L.A.; Butler, J.S.; Klinge, C.M.; Schaner Tooley, C.E. Loss of the N-terminal methyltransferase NRMT1 increases sensitivity to DNA damage and promotes mammary oncogenesis. Oncotarget 2015, 6, 12248–12263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Zhang, J.; Song, H.; Chen, C.; Chen, L.; Dai, Y.; Sun, P.H.; Zou, C.; Wang, X. Methyltransferase-like protein 11A promotes migration of cervical cancer cells via up-regulating ELK3. Pharmacol. Res. 2021, 172, 105814. [Google Scholar] [CrossRef] [PubMed]
  13. Catlin, J.P.; Marziali, L.N.; Rein, B.; Yan, Z.; Feltri, M.L.; Schaner Tooley, C.E. Age-related neurodegeneration and cognitive impairments of NRMT1 knockout mice are preceded by misregulation of RB and abnormal neural stem cell development. Cell Death Dis. 2021, 12, 1014. [Google Scholar] [CrossRef]
  14. Mackie, B.D.; Chen, D.; Dong, G.; Dong, C.; Parker, H.; Schaner Tooley, C.E.; Noinaj, N.; Min, J.; Huang, R. Selective Peptidomimetic Inhibitors of NTMT1/2: Rational Design, Synthesis, Characterization, and Crystallographic Studies. J. Med. Chem. 2020, 63, 9512–9522. [Google Scholar] [CrossRef] [PubMed]
  15. Chen, D.; Dong, G.; Deng, Y.; Noinaj, N.; Huang, R. Structure-based Discovery of Cell-Potent Peptidomimetic Inhibitors for Protein N-Terminal Methyltransferase 1. ACS Med. Chem. Lett. 2021, 12, 485–493. [Google Scholar] [CrossRef]
  16. Zhang, L.; Torgerson, T.R.; Liu, X.Y.; Timmons, S.; Colosia, A.D.; Hawiger, J.; Tam, J.P. Preparation of functionally active cell-permeable peptides by single-step ligation of two peptide modules. Proc. Natl. Acad. Sci. USA 1998, 95, 9184–9189. [Google Scholar] [CrossRef] [Green Version]
  17. Ben-Dror, S.; Bronshtein, I.; Wiehe, A.; Roder, B.; Senge, M.O.; Ehrenberg, B. On the correlation between hydrophobicity, liposome binding and cellular uptake of porphyrin sensitizers. Photochem. Photobiol. 2006, 82, 695–701. [Google Scholar] [CrossRef] [PubMed]
  18. Li, Y.; Li, W.; Xu, Z. Improvement on Permeability of Cyclic Peptide/Peptidomimetic: Backbone N-Methylation as A Useful Tool. Mar. Drugs 2021, 19, 311. [Google Scholar] [CrossRef]
  19. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739–1749. [Google Scholar] [CrossRef]
  20. Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.; Mainz, D.T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006, 49, 6177–6196. [Google Scholar] [CrossRef] [Green Version]
  21. Kong, X.; Brooks, C.L., III. λ Dynamics: A New Approach to Free Energy Calculations. J. Chem. Phys. 1996, 105, 2414–2423. [Google Scholar] [CrossRef]
  22. Knight, J.L.; Brooks, C.L., III. Multisite λ Dynamics for Simulated Structure-Activity Relationship Studies. J. Chem. Theory Comput. 2011, 7, 2728–2739. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Keränen, H.; Pérez-Benito, L.; Ciordia, M.; Delgado, F.; Steinbrecher, T.B.; Oehlrich, D.; van Vlijmen, H.W.T.; Trabanco, A.A.; Tresadern, G. Acylguanidine Beta Secretase 1 Inhibitors: A Combined Experimental and Free Energy Perturbation Study. J. Chem. Theory Comput. 2017, 13, 1439–1453. [Google Scholar] [CrossRef]
  24. Wheeler, S.E.; Houk, K.N. Substituent Effects in the Benzene Dimer are Due to Direct Interactions of the Substituents with the Unsubstituted Benzene. J. Am. Chem. Soc. 2008, 130, 10854–10855. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Jorgensen, W.L.; Severance, D.L. Aromatic-Aromatic Interactions: Free Energy Profiles for the Benzene Dimer in Water, Chloroform, and Liquid Benzene. J. Am. Chem. Soc. 1990, 112, 4768–4774. [Google Scholar] [CrossRef]
  26. Nishio, M. CH/π hydrogen bonds in crystals. Cryst. Eng. Comm. 2004, 6, 130–158. [Google Scholar] [CrossRef]
  27. Shields, K.M.; Tooley, J.G.; Petkowski, J.J.; Wilkey, D.W.; Garbett, N.C.; Merchant, M.L.; Cheng, A.; Schaner Tooley, C.E. Select Human Cancer Mutants of NRMT1 Alter Its Catalytic Activity and Decrease N-Terminal Trimethylation. Protein Sci. 2017, 26, 1639–1652. [Google Scholar] [CrossRef] [Green Version]
  28. Kansy, M.; Senner, F.; Gubernator, K. Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes. J. Med. Chem. 1998, 41, 1007–1010. [Google Scholar] [CrossRef]
  29. Avdeef, A.; Strafford, M.; Block, E.; Balogh, M.P.; Chambliss, W.; Khan, I. Drug Absorption in Vitro Model: Filter-Immobilized Artificial Membranes: 2. Studies of the Permeability Properties of Lactones in Piper Methysticum Forst. Eur. J. Pharm. Sci. 2001, 14, 271–280. [Google Scholar] [CrossRef]
  30. Chen, X.; Murawski, A.; Patel, K.; Crespi, C.L.; Balimane, P.V. A Novel Design of Artificial Membrane for Improving the PAMPA Model. Pharm. Res. 2008, 25, 1511–1520. [Google Scholar] [CrossRef]
Molecules 27 01381 g001 550
Figure 1. Optimization strategy of cell-potent peptidomimetic NTMT1 inhibitors.
Figure 1. Optimization strategy of cell-potent peptidomimetic NTMT1 inhibitors.
Molecules 27 01381 g001
Molecules 27 01381 sch001 550
Scheme 1. Synthetic route for peptidomimetic inhibitors 1a–k.
Scheme 1. Synthetic route for peptidomimetic inhibitors 1a–k.
Molecules 27 01381 sch001
Molecules 27 01381 g002 550
Figure 2. Docking studies of the peptidomimetic inhibitors through Glide. (A) Linear regression model of IC50 values and docking scores of the inhibitors. (B–D) Representative docking models of GD556, GD590, and GD591. The NTMT1 is shown in the color ribbon. The peptidomimetic inhibitors are shown in the green stick, and the interacting residues are shown in the gray stick. The H-bonds are shown in green–dotted lines.
Figure 2. Docking studies of the peptidomimetic inhibitors through Glide. (A) Linear regression model of IC50 values and docking scores of the inhibitors. (B–D) Representative docking models of GD556, GD590, and GD591. The NTMT1 is shown in the color ribbon. The peptidomimetic inhibitors are shown in the green stick, and the interacting residues are shown in the gray stick. The H-bonds are shown in green–dotted lines.
Molecules 27 01381 g002
Molecules 27 01381 g003 550
Figure 3. Computational studies through alchemical free energy calculations. (A) Correlation between MSλD computed and experimental binding affinities for DC541 and 1a–h. The best fit line (red, dashed) matches well the ideal y = x line (black, solid). Trajectory snapshots highlight π stacking and CH—π interactions (orange, dashes for 1d (B) and 1f (C)).
Figure 3. Computational studies through alchemical free energy calculations. (A) Correlation between MSλD computed and experimental binding affinities for DC541 and 1a–h. The best fit line (red, dashed) matches well the ideal y = x line (black, solid). Trajectory snapshots highlight π stacking and CH—π interactions (orange, dashes for 1d (B) and 1f (C)).
Molecules 27 01381 g003
Molecules 27 01381 g004 550
Figure 4. Cytotoxicity studies of the peptidomimetic inhibitors via alamarBlue assay (n = 3). (A) The effects of 1a, 1b, 1g, and 1h on growth in normal HCT116 cells. (B) The effects of 1a (GD556) on growth in both normal and NTMT1 knockout HCT116 cells.
Figure 4. Cytotoxicity studies of the peptidomimetic inhibitors via alamarBlue assay (n = 3). (A) The effects of 1a, 1b, 1g, and 1h on growth in normal HCT116 cells. (B) The effects of 1a (GD556) on growth in both normal and NTMT1 knockout HCT116 cells.
Molecules 27 01381 g004
Molecules 27 01381 g005 550
Figure 5. Inhibition of cellular N-terminal methylation by peptidomimetic inhibitors in HCT116 cells. Representative Western blot results of the effects of GD562 (A), GD564 (B), and GD573 (C) on the cellular methylation level. Image quantification was performed using ImageJ software (NIH). All bands were compared to the respective untreated control, which was set at 1.0. All experiments were performed in duplicate (n = 2).
Figure 5. Inhibition of cellular N-terminal methylation by peptidomimetic inhibitors in HCT116 cells. Representative Western blot results of the effects of GD562 (A), GD564 (B), and GD573 (C) on the cellular methylation level. Image quantification was performed using ImageJ software (NIH). All bands were compared to the respective untreated control, which was set at 1.0. All experiments were performed in duplicate (n = 2).
Molecules 27 01381 g005
Molecules 27 01381 g006 550
Figure 6. In-house selectivity studies of GD562. The compound was tested at 100, 30, and 10 µM (n = 2). Both SAM and substrate are at their Km values.
Figure 6. In-house selectivity studies of GD562. The compound was tested at 100, 30, and 10 µM (n = 2). Both SAM and substrate are at their Km values.
Molecules 27 01381 g006
Table
Table 1. SAR of synthesized compounds with modifications at C-region.
Table 1. SAR of synthesized compounds with modifications at C-region.
Molecules 27 01381 i001
IDRIC50 (μM)cLogPIC50/IC50 (DC541)
DC541 Molecules 27 01381 i0020.34 ± 0.030.71.0
1a (GD556) Molecules 27 01381 i0030.17 ± 0.0082.90.50
1b (GD558) Molecules 27 01381 i0040.18 ± 0.0072.90.53
1c (GD560) Molecules 27 01381 i0050.91 ± 0.031.72.7
1d (GD562) Molecules 27 01381 i0060.93 ± 0.041.92.7
1e (GD573) Molecules 27 01381 i0070.65 ± 0.012.31.9
1f (GD564) Molecules 27 01381 i0080.94 ± 0.032.42.8
1g (GD566) Molecules 27 01381 i0090.58 ± 0.032.51.7
1h (GD568) Molecules 27 01381 i0100.82 ± 0.072.52.4
1i (GD589) Molecules 27 01381 i0111.7 ± 0.072.35.0
1j (GD590) Molecules 27 01381 i0122.5 ± 0.093.87.4
1k (GD591) Molecules 27 01381 i0130.69 ± 0.083.82.0
N.D. = not determined. All experiments were performed in duplicates (n = 2) and presented as mean ± standard deviation (SD).
Table
Table 2. Cellular N-terminal methylation inhibition, cytotoxicity, and permeability of compounds 1c–k.
Table 2. Cellular N-terminal methylation inhibition, cytotoxicity, and permeability of compounds 1c–k.
IDGI50 (μM)Cellular IC50 (μM)Permeability
(10−6 cm/s)
1c (GD560)>300<3000.24 ± 0.06
1d (GD562)>300~500.26 ± 0.06
1e (GD573)>300~1000.17 ± 0.08
1f (GD564)>300~1000.47 ± 0.07
1g (GD566)128 ± 20<3000.6 ± 0.1
1h (GD568)135 ± 23<3000.9 ± 0.2
1j (GD590)N.DN.D.0.9 ± 0.3
1k (GD591)65 ± 7N.D.1.3 ± 0.4
Note: Verapamil was used as the positive control and was 8.6 ± 0.98 × 10−6 cm/s in the PAMPA assay. All experiments were performed in duplicate (n = 2) and presented as mean ± SD. N.D. = not determined.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Dong, G.; Iyamu, I.D.; Vilseck, J.Z.; Chen, D.; Huang, R. Improved Cell-Potent and Selective Peptidomimetic Inhibitors of Protein N-Terminal Methyltransferase 1. Molecules 2022, 27, 1381. https://doi.org/10.3390/molecules27041381

AMA Style

Dong G, Iyamu ID, Vilseck JZ, Chen D, Huang R. Improved Cell-Potent and Selective Peptidomimetic Inhibitors of Protein N-Terminal Methyltransferase 1. Molecules. 2022; 27(4):1381. https://doi.org/10.3390/molecules27041381

Chicago/Turabian Style

Dong, Guangping, Iredia D. Iyamu, Jonah Z. Vilseck, Dongxing Chen, and Rong Huang. 2022. "Improved Cell-Potent and Selective Peptidomimetic Inhibitors of Protein N-Terminal Methyltransferase 1" Molecules 27, no. 4: 1381. https://doi.org/10.3390/molecules27041381

APA Style

Dong, G., Iyamu, I. D., Vilseck, J. Z., Chen, D., & Huang, R. (2022). Improved Cell-Potent and Selective Peptidomimetic Inhibitors of Protein N-Terminal Methyltransferase 1. Molecules, 27(4), 1381. https://doi.org/10.3390/molecules27041381

Article Metrics

Back to TopTop